Are pharmaceutical companies pulling their money out of the United Kingdom because of Trump? How is biotech M&A pacing this year? And what will vaccine advisors discuss at their closely watched meeting this week?

We discuss all that and more on this week’s episode of “The Readout LOUD.”

STAT’s European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere. We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche’s $3.5 billion acquisition of 89bio and its MASH drug, announced this week.

For Andrew’s story on why pharmaceutical companies are pulling out of the U.K., go here ; to learn more about Merck halting its U.K. research operations,

See Full Page